FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to gene engineering structures for angiogenesis stimulation, and can be used in medicine for treating diseases caused by blood tissue disorders. Disclosed is a plasmid bicistronic construct carrying the human hepatocyte growth factor hHGF gene and the vascular endothelial growth factor hVEGF165 gene with two separate promoters for each of the genes: cytomegalovirus promoter - pCMV for HGF gene and gene promoter chicken β-actin - pCAG for VEGF165 gene. Bicistronic structure can be used as a medicinal agent for stimulating angiogenesis, growth and remodeling of vessels, as well as restoration of blood supply in ischemic tissues.
EFFECT: invention enables achieving optimal concentrations and ratio of angiogenic growth factors (AGF).
6 cl, 7 tbl, 1 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| CLOSED-CIRCULAR DNA (CCDNA) AND USE IN METHODS FOR REDUCING IMMUNE RESPONSE ASSOCIATED WITH GENE THERAPY OR NUCLEIC ACID THERAPY | 2020 |
|
RU2829367C2 |
| ENGINEERED ADENO-ASSOCIATED (AAV) VECTORS FOR TRANSGENE EXPRESSION | 2020 |
|
RU2839774C2 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| COMPOSITIONS AND METHODS FOR EXPRESSING SEVERAL BIOLOGICALLY ACTIVE POLYPEPTIDES FROM ONE VECTOR FOR THE TREATMENT OF HEART DISEASES AND OTHER PATHOLOGIES | 2016 |
|
RU2758489C2 |
| CLOSED-ENDED DNA VECTORS OBTAINED BY CELL-FREE SYNTHESIS, AND METHOD OF PRODUCING CEDNA VECTORS | 2019 |
|
RU2820586C2 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
| NON-VIRAL DNA VECTORS AND THEIR USE FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS | 2019 |
|
RU2800914C2 |
